PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23730417-0	2013	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer.	Oxaliplatin	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	81-85	
23730417-6	2013	In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51).	Oxaliplatin	36-47	KRAS proto-oncogene, GTPase	Homo sapiens	100-104	
23730417-6	2013	In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51).	Oxaliplatin	36-47	KRAS proto-oncogene, GTPase	Homo sapiens	143-147	
23730417-11	2013	In multivariate analyses, KRAS mutation remains an independent predictive factor for longer PFS in first-line oxaliplatin-based regimens.	Oxaliplatin	110-121	KRAS proto-oncogene, GTPase	Homo sapiens	26-30	
23730417-12	2013	In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	49-53	
23730417-12	2013	In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC.	Oxaliplatin	15-26	KRAS proto-oncogene, GTPase	Homo sapiens	101-105